FDA Crackdown on Telehealth and GLP-1 Drug Marketing Sparks Industry Shift
The FDA is cracking down on telehealth marketing related to GLP-1 drugs, focusing on unapproved weight loss medications. This industry action may disrupt prescribing practices and affect patient access. The crackdown signals increased regulatory scrutiny in the telehealth sector.
· 85d ago
